Every 8-K that Nuvectis Pharma, Inc. (NVCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVCT filings page.
Nuvectis Pharma, Inc. (NVCT) established a new “at the market” equity offering program by entering into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026. Under this arrangement, Nuvectis may sell shares of its common stock from time to time through Jefferies as sales agent, in transactions deemed an “at the market offering” under Rule 415(a)(4). The program is supported by a new Form S-3 shelf registration statement registering $200 million in securities, for which a prospectus supplement is expected to be filed on August 21, 2026.
Jefferies will use commercially reasonable efforts to place shares but is not obligated to sell any specific amount, and there is no escrow or similar arrangement for proceeds. Nuvectis will pay Jefferies up to 3.0% of the gross proceeds from any shares sold and reimburse certain costs, while providing customary indemnification. On July 20, 2026, Nuvectis terminated its prior at-the-market offering program and related prospectus supplement; no further sales will occur under that prior program.
Nuvectis Pharma, a clinical-stage biopharmaceutical company focused on complement-mediated diseases and oncology, in-licensed new lead candidate ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, and NXP200, an oral brain-penetrant BRAF inhibitor. Ciprocopan recently received its first marketing approval in China for treating paroxysmal nocturnal hemoglobinuria patients not previously treated with complement inhibitors through partner Haisco, representing the first global approval of a once-daily oral Complement Factor B inhibitor. In July 2026, the company completed a $115 million follow-on offering to provide resources for advancing NXP100 and its oncology portfolio.
For the quarter ended June 30 2026, cash and cash equivalents were $22.2 million. Net loss was $7.0 million compared with $6.3 million a year earlier, driven by research and development expenses of $4.7 million and general and administrative expenses of $2.5 million. Basic and diluted net loss per share was $0.30, based on 23,475,989 weighted-average common shares outstanding.
Nuvectis Pharma, Inc. entered into an underwriting agreement for a firm commitment public offering of 5,000,000 shares of common stock at $20.00 per share, for expected gross proceeds of $100 million. Underwriters also have a 30‑day option to buy up to 750,000 additional shares.
The company expects net proceeds of about $93 million, or approximately $107 million if the underwriters fully exercise the option, after discounts and expenses. The offering is made under Nuvectis’ effective Form S‑3 shelf registration and is expected to close on or about July 1, 2026, subject to customary conditions.
Nuvectis plans to use the net proceeds to advance its pipeline programs NXP100, NXP200, and NXP900, hire additional personnel, fund capital expenditures, cover public company operating costs, and for other general corporate purposes.
Nuvectis Pharma, Inc. reported a change to its existing at-the-market stock sales arrangement with Leerink Partners. The company lowered the amount available for sales under its Sales Agreement prospectus to $5 million, meaning it can offer and sell up to that value of common stock over time.
At the same time, Nuvectis is suspending use of the current Sales Agreement prospectus and will not sell any shares under this arrangement unless and until a new prospectus, prospectus supplement, or registration statement is filed. The underlying Sales Agreement with Leerink Partners remains in full force and effect.
Nuvectis Pharma entered a strategic license agreement with Haisco Pharmaceutical Group for exclusive rights outside China (with certain Asia carve-outs) to two clinical-stage drugs, NXP100 and NXP200. Nuvectis will lead development, manufacturing, and commercialization in its territory, while Haisco continues current work in China.
As consideration, Nuvectis will pay Haisco an upfront $20 million, with up to $20 million in initial development milestones and up to an additional $1.4 billion tied to future development, regulatory, and commercial milestones, plus tiered high-single-digit to mid-teens royalties on net sales. The agreement is subject to financing conditions to ensure Nuvectis has sufficient capital to advance the programs.
NXP100 is a late-stage oral Complement Factor B inhibitor with positive Phase 3 data in paroxysmal nocturnal hemoglobinuria and supportive Phase 2 data in IgA nephropathy, while NXP200 is a brain-penetrant, paradox-breaker BRAF inhibitor with early signals of durable activity across several BRAF-mutated solid tumors.
Nuvectis Pharma, Inc. reported the results of its 2026 Annual Meeting and corrected a share count error in its proxy. The Definitive Proxy Statement had stated 27,668,036 common shares outstanding as of April 13, 2026; the correct number was 26,614,628 shares.
The company stated this correction does not affect the validity or outcome of any votes. Stockholders representing 16,193,686 shares, or 60.8% of the 26,614,628 shares outstanding on the record date, were present, establishing a quorum. Stockholders elected Class I director Ron Bentsur and ratified Kesselman & Kesselman as independent registered public accounting firm for the year ending December 31, 2026.
Nuvectis Pharma reported first quarter 2026 results and highlighted progress in its NXP900 oncology program. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million as of December 31, 2025, reflecting ongoing development spending.
The company recorded a net loss of $6.1 million for the quarter, compared with $5.3 million a year earlier, as research and development expenses rose to $4.1 million and general and administrative expenses to $2.2 million. Net loss per share was $0.26 based on 23.4 million weighted average shares outstanding.
Nuvectis is advancing NXP900, an oral small molecule SRC Family Kinase inhibitor, in an ongoing Phase 1b study, with a preliminary data readout expected in the summer of 2026. Preclinical data presented at AACR showed synergistic activity when NXP900 was combined with sotorasib in non-small cell lung cancer models.
Nuvectis Pharma, Inc. reported wider losses for 2025 as it advanced its lead oncology candidate NXP900 through early-stage clinical development. Cash and cash equivalents were $31.6 million as of December 31, 2025, up from $18.5 million a year earlier, mainly from a February 2025 public offering and use of its at-the-market facility.
The company’s net loss was $26.4 million for 2025 compared with $19.0 million in 2024, driven by higher research and development and general and administrative expenses, including $6.0 million of non-cash stock-based compensation and $2.4 million of one-time license milestone fees. Research and development expenses rose to $18.2 million, while general and administrative costs increased to $9.4 million.
Management highlighted progress in the NXP900 program, including an ongoing Phase 1b monotherapy study across selected tumor types and a combination study with osimertinib in EGFR-mutated NSCLC, with a lorlatinib combination in ALK-positive NSCLC pending initiation. The company believes its current cash can fund multiple NXP900 Phase 1b milestones and operations well into the second half of 2027.
Nuvectis Pharma, Inc. filed an 8‑K to furnish a press release providing a corporate update and financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under the Exchange Act.
The company’s common stock trades on the Nasdaq Capital Market under the symbol NVCT. The filing also includes the iXBRL cover page as Exhibit 104.
Nuvectis Pharma, Inc. filed a current report to disclose that its Board of Directors appointed Juan Sanchez, MD as a new director on September 22, 2025. He will serve on the Board until his term expires at the 2026 annual meeting of stockholders, when he is expected to stand for election by stockholders.
The company states that Dr. Sanchez has no arrangements or understandings with any other person related to his appointment, no family relationships with existing directors or executive officers, and no material interests in related-party transactions as described under Item 404(a) of Regulation S-K. Nuvectis announced his appointment in a press release dated September 25, 2025, which is included as an exhibit to the report.